1
|
Mazonakis M, Kachris S, Tolia M, Damilakis J. NTCP Calculations of Five Different Irradiation Techniques for the Treatment of Thymoma. Curr Oncol 2023; 30:7740-7752. [PMID: 37623042 PMCID: PMC10453123 DOI: 10.3390/curroncol30080561] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 08/07/2023] [Accepted: 08/17/2023] [Indexed: 08/26/2023] Open
Abstract
This study provided normal tissue complication probability (NTCP) calculations from photon radiotherapy techniques in eleven patients with thymoma. Five plans were created for each participant using three-dimensional conformal radiotherapy (3D-CRT), five-field intensity modulated radiotherapy (5F-IMRT), seven-field IMRT (7F-IMRT), and volumetric modulated arc therapy with full arcs (FA-VMAT) and partial arcs (PA-VMAT). The target coverage, homogeneity index and conformation number for the planning target volume (PTV) and dosimetric parameters for the organs-at-risk (OARs) were taken from the fifty-five generated plans. The patient-specific NTCP of the lungs, heart and esophagus was calculated with an in-house software tool using differential dose-volume histograms and the equivalent uniform dose model. The PTV dose metrics from 3D-CRT were inferior to those from IMRT and VMAT plans. The dose constraints for the OARs were met in all treatment plans. The NTCP range of the lungs, heart and esophagus was 0.34-0.49%, 0.03-0.06% and 0.08-0.10%, respectively. The NTCPs of the heart for the incidence of peridarditis from IMRT and VMAT were significantly smaller than those from conformal treatment (p < 0.05). The 7F-IMRT was significantly superior to FA-VMAT in reducing the NTCP of the lungs and the risk of pneumonitis (p = 0.001). Similar superiority of 5F-IMRT over PA-VMAT for lung protection was found (p = 0.009). The presented results may be employed in the selection of the appropriate irradiation technique for restricting the complications in the adjacent OARs.
Collapse
Affiliation(s)
- Michalis Mazonakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, 71003 Iraklion, Greece;
| | - Stefanos Kachris
- Department of Radiotherapy and Oncology, University Hospital of Iraklion, 71110 Iraklion, Greece; (S.K.); (M.T.)
| | - Maria Tolia
- Department of Radiotherapy and Oncology, University Hospital of Iraklion, 71110 Iraklion, Greece; (S.K.); (M.T.)
| | - John Damilakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, 71003 Iraklion, Greece;
| |
Collapse
|
2
|
Mazonakis M, Tzanis E, Lyraraki E, Damilakis J. Automatic Radiobiological Comparison of Radiation Therapy Plans: An Application to Gastric Cancer. Cancers (Basel) 2022; 14:cancers14246098. [PMID: 36551582 PMCID: PMC9776876 DOI: 10.3390/cancers14246098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 12/08/2022] [Accepted: 12/09/2022] [Indexed: 12/14/2022] Open
Abstract
(1) Aim: This study was conducted to radiobiologically compare radiotherapy plans for gastric cancer with a newly developed software tool. (2) Methods: Treatment planning was performed on two computational phantoms simulating adult male and female patients. Three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) plans for gastric cancer were generated with three-photon beam energies. The equivalent uniform dose (EUD), tumor control probability (TCP) of the target and normal tissue control probability (NTCP) of eight different critical organs were calculated. A new software was employed for these calculations using the EUD-based model and dose-volume-histogram data. (3) Results: The IMRT and VMAT plan led to TCPs of 51.3-51.5%, whereas 3D-CRT gave values up to 50.2%. The intensity-modulated techniques resulted in NTCPs of (5.3 × 10-6-3.3 × 10-1)%. The corresponding NTCPs from 3D-CRT were (3.4 × 10-7-7.4 × 10-1)%. The above biological indices were automatically calculated in less than 40 s with the software. (4) Conclusions: The direct and quick radiobiological evaluation of radiotherapy plans is feasible using the new software tool. The IMRT and VMAT reduced the probability of the appearance of late effects in most of the surrounding critical organs and slightly increased the TCP compared to 3D-CRT.
Collapse
Affiliation(s)
- Michalis Mazonakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, 71003 Iraklion, Greece
- Correspondence:
| | - Eleftherios Tzanis
- Department of Medical Physics, Faculty of Medicine, University of Crete, 71003 Iraklion, Greece
| | - Efrossyni Lyraraki
- Department of Radiation Oncology, University Hospital of Iraklion, 71110 Iraklion, Greece
| | - John Damilakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, 71003 Iraklion, Greece
| |
Collapse
|
3
|
Mattei P, Chabrillac E, Cabarrou B, Dupret-Bories A, Vergez S, Sarini J, Lopez R, Piram L, Brun T, Modesto A. Adjuvant brachytherapy for oral squamous cell carcinomas: a single-center experience comparing low-dose and pulsed-dose-rate techniques. Strahlenther Onkol 2022; 198:150-158. [PMID: 34786604 DOI: 10.1007/s00066-021-01870-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Accepted: 10/17/2021] [Indexed: 10/19/2022]
Abstract
OBJECTIVE This study aims to assess the outcomes of adjuvant interstitial brachytherapy (BT) to the tumor bed for oral cavity squamous cell carcinoma (SCC), and to compare the oncological outcomes and toxicity profile of low-dose-rate (LDR) and pulsed-dose-rate (PDR) BT. DESIGN This retrospective single-center study included all patients who underwent postoperative LDR- or PDR-BT to the tumor bed as the sole adjuvant treatment for an oral tongue or floor of the mouth SCC between January 2000 and December 2020. RESULTS A total of 79 patients were eligible for this study. The cohort was divided into an LDR group (n = 38) and a PDR group (n = 41). The median time interval between surgery and brachytherapy was 55 days. Median delivered total dose was 55 Gy and median hospital stay was 5 days. Five patients (8.3%) experienced grade 3-4 early toxicity, 2 in the LDR group and 3 in the PDR group. Late toxicities were present in 28 patients (44.4%) and were dominated by grade 1-2 residual pain and dysesthesia, without a statistical difference between the groups. After a median follow-up of 65.1 months, 5‑year local control (LC), disease-free survival (DFS), and overall survival (OS) for the whole cohort were 76.3% (95% CI = 63.4-85.1), 61.6% (95% CI = 49.0-72.0), and 71.4% (95% CI = 58.6-80.8), respectively. CONCLUSION Adjuvant BT after excision of oral cavity SCC provides satisfactory oncological outcomes along with good tolerance. In our study, PDR-BT showed similar oncological and functional results to LDR-BT in this indication.
Collapse
Affiliation(s)
- Pierre Mattei
- Department of Surgery, University Cancer Institute Toulouse-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France.
| | - Emilien Chabrillac
- Department of Surgery, University Cancer Institute Toulouse-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France
| | - Bastien Cabarrou
- Department of Biostatistics, Institut Claudius Regaud, University Cancer Institute Toulouse-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France
| | - Agnès Dupret-Bories
- Department of Surgery, University Cancer Institute Toulouse-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France
| | - Sébastien Vergez
- Department of Surgery, University Cancer Institute Toulouse-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France
- Department of Head and Neck Surgery, Centre Hospitalier Universitaire Rangueil-Larrey, 24 Chemin de Pouvourville, 31400, Toulouse, France
| | - Jérôme Sarini
- Department of Surgery, University Cancer Institute Toulouse-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France
| | - Raphaël Lopez
- Department of Maxillofacial Surgery, Toulouse University Hospital, Pierre-Paul Riquet Hospital, Allée Jean Dausset, 31300, Toulouse, France
| | - Lucie Piram
- Department of Radiation Therapy, University Cancer Institute Toulouse-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France
| | - Thomas Brun
- Department of Engineering and Medical Physics, University Cancer Institute Toulouse-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France
| | - Anouchka Modesto
- Department of Radiation Therapy, University Cancer Institute Toulouse-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France
| |
Collapse
|